PIK3CA and breast cancer: This systematic review and meta-analysis included five randomized controlled trials and demonstrated that combining PI3K inhibitors with fulvestrant confers significant clinical benefits in advanced breast cancer, particularly by prolonging PFS and enhancing the ORR.